Reports for NATAP

1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment

July 7-11, 2001 Buenos Aires, Argentina

• Gender Differences in Morphologic Alterations (Body Changes or Lipodystrophy)
  (8/27/01)
  
  
• Mother-to-Child Transmission
  (8/27/01)
  
  
• Role of HAART in Development of Hypertension Among HIV-Infected Women
  (8/27/01)
  
  
• Access to Care for Women
  (8/27/01)
  
  
• Platelet Counts; Elevated Lipids; Thymosin alpha-1 for HBV; treating HCV in methadone, psychiatric, and former drug users, Hepatotoxicity in HIV in the ACTG
  -- Platelet Count May Predict HCV Liver Disease Progression ..>
  -- Elevated Cholesterol/Triglycerides May Be Associated With Accelerated Liver Disease Progression; Treatment May Slow Progression ..>
  -- Meta-Analysis of Thymosin Alpha Treatment for Hepatitis B ..>
  -- Thymosin Alpha for Treatment of Hepatitis B ..>
  -- Psychiatric Patients, Methadone Patients, and Earlier Drug Users Can Be Treated for HCV When Given Adequate Support Services ..>
  -- Hepatotoxicity in the US Adult Clinicals Trials Group ..>
     (from the Digestive Disease Week Liver Conference)
  (7/11/01)
  
  
• Abacavir and 3TC Once Daily
  (8/13/01)
  
  Two Four-Drug Therapy Studies at IAS: are 4 drugs better than 3?
       written for NATAP by Michael Norton, PA
  (8/09/01)
  
  
• Dietary Supplements for Nelfinavir-Associated Diarrhea: acidophilus/bifidobacteria (1.2g/d) and soluble fiber (11g/d) supplements and L-Glutamine
  (8/05/01)
  
  
• HPV Infection in Women and Men
       Written for NATAP by Danielle Milano, MD
  (8/02/01)
  
  
• 3 Indinavir + Ritonavir Studies
       Written for NATAP by Michael Norton, PA
     Abstract #745 – Direct Study
     Abstract #750 – Edwin DeJesus, et.al
     Abstract #60 – Best Study
  (8/01/01)
  
  
• Highlights from the 1st IAS Conference on HIV Pathogenesis and Treatment
  (7/30/01)
  
  
• Report 1 from IAS (Intl AIDS Society) Conference
       Reported by Michael Norton, PA
  (7/30/01)
  
  
• Buenos Aires Summary
       Written for NATAP by Nancy Shulman, MD, Stanford University
  (7/30/01)
  
  
• STI vs Continuous HAART during Chronic HIV Infection
       Written for NATAP by Michael Norton, PA
  (7/30/01)
  
  
• Effects of Prolonged Discontinuation of Successful Antiretroviral Therapy
       Written for NATAP by Michael Norton, PA
  (7/30/01)
  
  
• 3 Year Durability of Efavirenz in the 006 Study
  (7/30/01)
  
  

Clinical Trials Presentations:

• Atazanavir (TAZ) (BMS-232632)
  (7/30/01)
  
  
• Abacavir+Combivir vs Indinavir+Combivir
  (7/30/01)
  
  
• Tipranavir (TPV): new PI for individuals with PI resistance, 48 week data
  (7/30/01)